Narcotic Analgesics

FDA Committee Votes on First-of-Its-Kind Pain Drug Oliceridine

By October 12, 2018

Oliceridine, a G-protein biased mu-opioid receptor (MOR) ligand, has a unique mechanism of action that allows for more selective pathway activation while avoiding a pathway associated with opioid-related adverse events.

'Urgent' Need for Cannabinoid Trials in Ped Neurologic Disorders

September 21, 2018

Parents use unregulated cannabinoids to manage neurological disorders in children, including seizures, spasticity, and irritability in children with epilepsy, autism-spectrum disorder, and cerebral palsy.

Investigational Tx Shows Promise in Chronic Low Back Pain

By September 19, 2018

An investigational treatment - CAM2038 (Braeburn) - currently under review for the treatment of moderate-to-severe opioid use disorder, has demonstrated a reduction in Chronic Low Back Pain (CLBP) compared to placebo in patients previously on long-term daily opioid therapy.

US Senate Passes Opioids Bill

September 19, 2018

Five different committees submitted more than 70 proposals to help craft the bill, called the Opioid Crisis Response Act of 2018.

FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products

By September 18, 2018

As part of the REMS program, drug companies with approved opioid analgesics must make training available to prescribers and provide unrestricted grants to accredited continuing education providers for the development of education courses.

CDC: About 1 in 5 US Adults Have Chronic Pain

September 14, 2018

The prevalences of both chronic pain and high-impact chronic pain were higher among women; older adults; adults who were previously, but not currently, employed; adults living in poverty; those with public health insurance; and rural residents.

Cassipa Approved as Maintenance Treatment for Opioid Dependence

By September 10, 2018

Cassipa combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist.

Designer opioid receptor agonist provides pain relief without side effects

September 08, 2018

Mu opioid peptide (MOP) receptor agonists provide effective pain relief, but are associated with severe side effects such as respiratory depression, opioid-induced hyperalgesia, dependence, and abuse.

With New Persistent Opioid Use, Most Early Scripts From Surgeons

September 07, 2018

But in the longer term, the majority of opioid prescriptions come from primary care physicians

FDA Outlines Plan for New Analgesic Guidance to Combat Opioid Crisis

By August 31, 2018

The new plan will break out the current guidance into 4 separate guidances.

Clinical guidelines may lead to better prescribing practices

August 30, 2018

Following clinical guidelines release, decreases were observed in the overall rate of opioid prescribing. 2. Guidelines may be associated with reduced high-dosage opioid prescriptions and the percentage of patients with overlapping benzodiazepine and opioid prescriptions.

PT Better After Hip Surgery Than Opioids in Younger Adults

August 29, 2018

For patients receiving both treatments, the group receiving opioids first had mean hip-related downstream costs that were significantly higher than the group receiving physical therapy first ($18,806 versus $16,955).

FDA Warning Letters Target Illegal Online Sales of Opioids

August 29, 2018

Americans who buy prescription medicines such as opioids from illegal online pharmacies may be putting their health at risk because the drugs may be counterfeit, contaminated, expired, or otherwise unsafe, according to the FDA.

Buprenorphine/Naloxone Rx Fills Up With Medicaid Expansion

August 28, 2018

After expansion, there was a significant increase in buprenorphine with naloxone fills per 100,000 county residents in expansion vs non-expansion counties (8.7).

Odds of Marijuana Use Up With Nausea, Vomiting in Pregnancy

August 27, 2018

The prevalence of prenatal marijuana use was 5.3% by self-report or toxicologic test findings; prevalence was greater among females with severe and mild versus no NVP (11.3 and 8.4, respectively, vs 4.5%).

Prescription Drug Monitoring Program May Not Cut Opioid Use

August 27, 2018

In the 6 months before the mandatory PDMP requirement, the mean number of opioid pills prescribed decreased from 30.8 to 24 (22.1%); in the 6 months after the legislation, the decrease was less, from 22.8 to 21.9 pills (3.9%).

Hydrocodone Schedule Change Affected Post-Op Opioid Rx

August 24, 2018

The researchers found that the mean oral morphine equivalents (OMEs) filled in the initial opioid prescription increased by about 35 after the schedule change (β = 35.1; P<.01), which was equivalent to seven hydrocodone tablets (5mg).

Pregabalin may increase the risk of death when coprescribed with opioids

August 21, 2018

Patients coprescribed opioids and pregabalin had significantly increased odds of opioid-related death compared to opioid prescription alone.

Odds of Death Up With Exposure to Pregabalin, Opioids

August 21, 2018

Dose-response association with highest odds of opioid-related death with high-dose prefabbing

DEA Proposal Will Significantly Cut Opioid Manufacturing in 2019

By August 20, 2018

Last year, the DEA proposed a 20% reduction in the manufacturing of controlled substances for 2018 compared to 2017.

Integration of Opioid, Infectious Disease Treatment Needed

August 15, 2018

"All health care providers have a role in combating the OUD epidemic and its infectious disease consequences. Those who treat infectious complications of OUD are well-suited to screen for OUD and begin treatment with effective US Food and Drug Administration-approved medications," the authors write.

CDC: EMS Administration of Naloxone Up From 2012 to 2016

August 13, 2018

This increase mirrored the 79.7% increase in opioid overdose mortality from 7.4 (deaths per 100,000 persons) to 13.3.

CDC: Rates of Opioid Use Disorder Seen at Time of Delivery Up

August 13, 2018

Rate of opioid use disorder at time of delivery quadrupled from 1999 to 2014

Which Opioids Are More Likely to Induce QT Interval Prolongation?

By August 07, 2018

Studies comparing MMT to buprenorphine maintenance treatment (BMT) over 5-years found buprenorphine to be a safer drug for opioid maintenance treatment as it had no significant effect on QT prolongation.

Opioid prescriptions for children with minor ailments linked to adverse events

August 07, 2018

Older children between the ages of 12 and 17 were more likely to be prescribed opioids and were more likely to suffer an adverse event. Definitively linking opioids with the risk of developing an adverse event was difficult to determine as incidence data on opioid use was not obtained.

Lucemyra Now Available for Mitigation of Opioid Withdrawal Symptoms

By August 06, 2018

Lucemyra is not indicated as a treatment for opioid use disorder.

FDA Issues Complete Response Letter Rejecting Remoxy Approval

By August 06, 2018

In June 2018, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee met and voted against (14-3) the approval of Remoxy upon data review.

FDA to Review Novel Opioid Analgesic for Chronic Low Back Pain

By July 30, 2018

This novel agent has low permeability across the blood-brain barrier, which slows its rate of entry into the brain and reduces dopamine release.

Outpatient Opioid Prescriptions for Children Often Filled

July 27, 2018

Dental procedures, outpatient procedure and/or surgery, trauma, and infections were the most common opioid indications.

Many US Adults View Marijuana Use Positively

July 25, 2018

Overall, 29.2% of US adults agreed that smoking marijuana prevents health problems. About 18 and 7.6% believe that exposure to secondhand marijuana smoke is somewhat or completely safe for adults and children, respectively.